SCHEMBL8568520

SCHEMBL8568520

O=[N+]([O-])c1ncccc1NCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.56
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 5/20 0.49
HTT P42858 2/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CRHBP P24387 1/20 0.49
CYP2C19 P33261 1/20 0.49
CRHR2 Q13324 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8562887 0.84 BACE1 (0.52) BACE1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL2483154 0.80 SMN1; SMN2 (0.46) POLBSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL8569474 0.77 HTT (0.49) BACE1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL1620480 0.77 KMT2A (0.43) POLBMEN1KMT2AMAPTHTT
SCHEMBL7697934 0.77 MAPT (0.59) SMN1; SMN2MEN1KMT2AMAPTRECQL
SCHEMBL6252735 0.76 L3MBTL1 (0.57) POLBMEN1KMT2AMAPTCYP1A2
SCHEMBL31631301 0.76 NPC1 (0.74) POLBSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1738419 0.76 NPC1 (0.74) POLBSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL8600948 0.76 MAPT (0.46) SMN1; SMN2MEN1KMT2AMAPTHTT
Fluoride SCHEMBL23234546 0.76 NPC1 (0.43) POLBMEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-23 US disclosed
CN-118974035-A 2-Aminoimidazole derivatives as PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-11-15 CN disclosed
EP-4426690-A2 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-09-11 EP disclosed
WO-2023081367-A2 2-AMINO IMIDAZOLE DERIVATIVES Mirati Therapeutics, Inc. (US) 2023-05-11 WO disclosed
CN-101723885-B Improved method for preparing diaminopyridine JUBILANT ORGANOSYS LTD 2013-02-13 CN disclosed
CN-101723885-A Improved method for preparing diaminopyridine JUBILANT ORGANOSYS LTD 2010-06-09 CN disclosed
EP-0735025-B1 Process for producing aminonitropyridines SUMITOMO CHEMICAL CO (JP) 1998-07-01 EP disclosed
US-5648496-A AMINATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-15 US disclosed
CN-1138033-A Process for produducing aminonitropyridines SUMITOMO CHEMICAL CO (JP) 1996-12-18 CN disclosed
EP-0735025-A1 Process for producing aminonitropyridines SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 BACE1 3899/4885POLB 2104/4885SMN1; SMN2 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.